PBX3

Across TCGA pan-cancer cohorts, PBX3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PBX3 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher PBX3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PBX3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

LUSC, UCEC, and PRAD are the cancer types where PBX3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.187	0.662	<.001	30	view →
UCEC	DFS	Median	II,III,IV	1.000	0.441	.020	10	view →
PRAD	DFS	Median	All	0.072	0.886	<.001	6	view →
STAD	DFS	Median	All	1.000	0.339	.044	4	view →
COAD	DFS	Median	II,III,IV	0.223	0.648	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PBX3–LUSC (OS)

Open the LUSC breakdown →